ensifentrine: Clinical Trials

15 trials of ensifentrine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2, 5 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 7, Active not recruiting 1
Phase 35Completed 4, Recruiting 1
Phase 12Completed 2

Follow ensifentrine: new trials by email Literature Review of ensifentrine trials Research Report on ensifentrine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
Ensifentrine, Placebo, Standard of Care (SOC) - Pulmonary Disease, Chronic Obstructive
Phase 3RecruitingMerck Sharp & Dohme LLC21362026-11-022026-11-16
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg - Chronic Obstructive Pulmonary Disease
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA332025-10-062026-01-08
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg - Chronic Obstructive Pulmonary Disease
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA4972025-07-312026-09-11
Effect of Ensifentrine Treatment on CAT Score
Ensifentrine 3 mg twice daily - COPD
Phase 3CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA202024-06-112025-04-18
A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedNuance Pharma (shanghai) Co., Ltd5262023-03-102025-06-04
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
Ensifentrine - Chronic Obstructive Pulmonary Disease
Phase 1CompletedNuance Pharma (shanghai) Co., Ltd282023-03-062023-04-24
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
Ensifentrine, Placebo, LABA/LAMA - Pulmonary Disease, Chronic Obstructive, COPD
Phase 2Active not recruitingVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA702022-05-272026-11-03
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA7632020-09-292023-11-13
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA7902020-09-222023-10-16
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium - COPD
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA4162019-05-012020-11-20
A Study of RPL554 in Patients With Cystic Fibrosis
RPL554, Placebo - Cystic Fibrosis
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA102017-02-082024-05-21
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium, Placebo plus tiotropium - Chronic Obstructive Pulmonary Disease Moderate
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA302017-01-012019-02-27
The Effects of RPL554 on Top of Standard COPD Reliever Medications
Salbutamol, Ipratropium, RPL554 - Chronic Obstructive Pulmonary Disease
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA362015-10-012016-09-09
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
RPL554, Salbutamol, Placebo - Asthma
Phase 2CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA292015-04-012016-09-09
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
RPL554, Placebo - Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder
Phase 1CompletedVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA1122014-12-012015-10-28

Conditions studied

Pulmonary Disease, Chronic Obstructive (12)  ·  Asthma (1)  ·  Cystic Fibrosis (1)  ·  Lung Diseases (1)

Sponsors

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA (12)  ·  Nuance Pharma (shanghai) Co., Ltd (2)  ·  Merck Sharp & Dohme LLC (1)

Countries

United States (8)  ·  United Kingdom (5)  ·  Bulgaria (2)  ·  China (2)  ·  Hungary (2)  ·  Poland (2)  ·  Slovakia (2)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Estonia (1)  ·  Germany (1)  ·  Greece (1)  ·  Romania (1)

Top investigators

Dave Singh (2)  ·  Andres Floto (1)  ·  Gary Ferguson (1)  ·  Johnston Stewart (1)  ·  Lief Bjermer (1)

Results publications

PMID 30166326, PMID 37364283, PMID 39106052, PMID 39197510, PMID 39854278, PMID 31202957, PMID 41710324, PMID 41895581

NIH funding

2015 (2)